The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
Refractory and/or Relapsed Metastatic Solid Tumors
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
-
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States, 33701
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States, 21231
Albert Einstein College of Medicine, Children's Hospital at Montefiore, Bronx, New York, United States, 10467
New York Medical Center/ Maria Fareri Children's Hospital, Valhalla, New York, United States, 10595
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
1 Year to 50 Years
ALL
No
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,
Heather Symons, MD, MHS, PRINCIPAL_INVESTIGATOR, Johns Hopkins University
2030-01